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Abstract
Objective: We recently demonstrated that 998 features derived from a simple
7-minute smartphone test could distinguish between controls, people with
Parkinson’s and people with idiopathic Rapid Eye Movement sleep behavior
disorder, with mean sensitivity/specificity values of 84.6-91.9%. Here, we inves-
tigate whether the same smartphone features can be used to predict future clin-
ically relevant outcomes in early Parkinson’s. Methods: A total of 237
participants with Parkinson’s (mean (SD) disease duration 3.5 (2.2) years) in
the Oxford Discovery cohort performed smartphone tests in clinic and at home.
Each test assessed voice, balance, gait, reaction time, dexterity, rest, and postu-
ral tremor. In addition, standard motor, cognitive and functional assessments
and questionnaires were administered in clinic. Machine learning algorithms
were trained to predict the onset of clinical outcomes provided at the next 18-
month follow-up visit using baseline smartphone recordings alone. The accu-
racy of model predictions was assessed using 10-fold and subject-wise cross val-
idation schemes. Results: Baseline smartphone tests predicted the new onset of
falls, freezing, postural instability, cognitive impairment, and functional impair-
ment at 18 months. For all outcome predictions AUC values were greater than
0.90 for 10-fold cross validation using all smartphone features. Using only the
30 most salient features, AUC values greater than 0.75 were obtained. Interpre-
tation: We demonstrate the ability to predict key future clinical outcomes using
a simple smartphone test. This work has the potential to introduce individual-
ized predictions to routine care, helping to target interventions to those most
likely to benefit, with the aim of improving their outcome.
Introduction
Significant heterogeneity in Parkinson’s influences clinical
presentation, progression, medication response, and dis-
ease complication risk. The Oxford Discovery and Track-
ing Parkinson’s cohorts provide around 2500 community-
ascertained patients, prospectively followed from early
diagnosis, in whom these phenotypic variations can be
studied.1 We used data-driven approaches to identify fast
and slow motor progressor subtypes, with differences akin
to the minimally clinically important 3-point difference
on the Movement Disorders Society Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) that neuroprotective
treatment trials are often powered to detect.1–3 While
such differences are observed in cohort studies, individu-
alized predictions remain challenging.
Disability in Parkinson’s is mainly determined by the
onset of postural instability, falls, freezing of gait, and
dementia.4,5 The time to reach these disease milestones
varies considerably, leading to increased outcome
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variation and requiring larger sample sizes to demonstrate
potential treatment effects.6 A number of models have
aimed to predict these clinically relevant outcomes. A 3-
step falls prediction tool by Paul et al. attached the great-
est weighting to whether individuals reported falling at
baseline, yet limited numbers prevented the prediction of
the onset of falls in those without falls at baseline, an out-
come of greater interest to the treating clinician.7,8
Ehgoetz et al. recently reported a logistic regression
model utilizing the Hospital Anxiety and Depression Scale
(HADS) and the Freezing of Gait (FOG) questionnaire
total score to predict the onset of future freezing, which
requires external validation.5 Velseboer et al. described a
similar model utilizing age, the numbers of animals
named in a verbal fluency task and the UPDRS axial score
to predict a composite adverse outcome but it was not
possible to distinguish between death, dementia or postu-
ral instability.9 Models to date have relied on combina-
tions of different clinical questionnaires and assessments,
requiring time and skill to administer, in order to make
specific predictions; to the best of our knowledge no sin-
gle test has been able to predict multiple future clinical
outcomes.
A multi-device study is being planned, that uses smart-
phones to capture questionnaire data and to store tremor
data recorded by smartwatches, alongside tablet-based
assessments, with the aim of differentiating Parkinson’s
from Essential Tremor.10 However so far, studies using
smartphones alone have focused on equipping the clinician;
in distinguishing individuals with and without Parkin-
son’s11,12 and working to derive smartphone scales with
which to measure disease severity.13,14 Our aim was to use
smartphone data to predict outcomes of direct clinical rele-
vance to people with Parkinson’s and clinicians, alike.
Methods
The Oxford Parkinson’s Disease (PD) Centre Discovery
study15 is a longitudinal cohort study that recruits partici-
pants with early Parkinson’s who fulfil the United King-
dom PD Brain Bank criteria for probable PD.16
Continued participation depends upon participants being
ascribed a probability of Parkinson’s of at least 90% by
trained researchers at their latest clinic assessment.17
Antecedent approval was granted by the local research
ethics committee, adhering to national legislation and the
Declaration of Helsinki. Participants provide written
informed consent to participate.
Since 2014, participants have been invited to perform
smartphone assessments. We analysed smartphone tests
performed at 18-monthly clinic visits and up to four
times a day for a maximum of seven days at home,
within a 3-month period of their clinic visit (see Fig. 1
for device details).18 Smartphone tests assess: (1) Voice
(participants hold the phone to their ear, take a deep
breath, and say “aaah” at a comfortable and steady tone
and level, for as long as possible); (2) Balance and (3)
Gait (with the phone in a trouser pocket or arm band,
participants stand still and then walk a distance of 20
yards before turning and walking back); (4) Dexterity
(participants tap alternately between two buttons on the
screen at a comfortable rate); (5) Non-cued reaction time
(participants press on a button as it appears on the
screen, keeping their finger down whilst it is there and
lifting their finger off as it disappears); (6) Rest and (7)
Postural tremor (participants hold the smartphone in the
hand most affected by tremor if they have tremor, or
their dominant hand if they do not, while their hand is at
rest or held outstretched in front of them).
The seven smartphone tasks take 6–7 min in total to
perform. All seven tasks constitute one smartphone
recording. Incomplete recordings, where all seven tasks
were not performed within a 15-min time period, were
excluded from analysis.
Clinical data collected at in-person 18-monthly longitu-
dinal clinic visits were matched to smartphone recordings
performed in clinic and at home within 3 months of the
clinic visit; henceforth referred to as a time window.
Smartphone recordings contributed at different time win-
dows, related to different longitudinal clinic visits, were
treated independently for the purpose of analysis. Smart-
phone recordings analyzed were collected between 8
August 2014 and 7 November 2017.
Future outcomes were defined according to the results
of clinical assessments and questionnaires performed at
the next 18-month clinic visit as detailed in (Table 1) and
included the new onset of (1) falls (>1 self-reported fall
in the preceding 6 months), (2) freezing (a freezing fre-
quency of at least “about once a month” on the FOG
questionnaire19), (3) Postural instability (Hoehn and
Yahr20 stage ≥ 3), (4) Cognitive impairment21 (a Mon-
treal Cognitive Assessment (MoCA)22 score < 26), (5)
Difficulty doing hobbies (MDS-UPDRS23 part II item 2.8
score ≥ 3 indicating major difficulty or an inability to do
activities of enjoyment) and (6) the self-reported need for
future help at home. Individuals who had already reached
a given milestone at the time of their smartphone record-
ing were excluded from the respective analysis. Similarly,
smartphone recordings missing the clinical data necessary
for the assessment of the outcome definition or meeting
exclusion criteria were excluded. All assessments were
done on existing medication.
Altogether 998 statistical features were extracted from
each smartphone recording as previously described.24
These features help characterize different motor symp-
toms associated with Parkinson’s. Typical examples of
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such features include variation in speech frequency and
amplitude, degree of turbulent noise in speech due to
incomplete vocal fold closure, tapping speed and rhythm,
mean reaction time, changes in body motion (such as
detrended fluctuation analysis) and association between
the tri-axial accelerometer sensor data (such as mutual
information). Statistical analyses were performed using
Matlab software (R2018a; Mathworks, USA).
Smartphone features were used to train machine learn-
ing algorithms (random forests) to predict each binary
clinical outcome of interest. Random forests is an ensem-
ble learning technique that has commonly been used for
a range of classification and regression applications.25 We
chose random forests as they are relatively robust to out-
liers and noisy features. Moreover, in previous smart-
phone-based studies, random forests have been shown to
be useful in distinguishing participants with RBD and
Parkinson’s from controls,18 and in predicting MDS-
UPDRS part III motor examination scores.12 To try and
avoid model overfitting, we used cross validation (CV)
which involves splitting the dataset into non-overlapping
training and test sets. The training data was used for
learning the underlying patterns of interest; the test data-
set for validating the model prediction accuracy. CV helps
assess the generalizability of the model to previously
unseen datasets. To test the accuracy of predictions, we
used two common methods of CV: (1) 10-fold CV, and
(2) leave one subject out (LOSO) CV.
Machine learning is also sensitive to the proportion of
data with and without the clinical outcome of interest
that is used to train the model. If there is an imbalance
in outcome between groups, for example, where signifi-
cantly more recordings from people without falls are used
to train a falls prediction model, high prediction
Figure 1. Smartphone models. In the search for a scalable solution to the quantification of motor symptoms in Parkinson’s, an Android based
smartphone app was installed on a range of consumer grade smartphones that were used in clinic and provided to participants to take home.
Participants also had the option of being sent a link to download the app onto their own Android smartphone. A specialized smartphone app
was used to collect the raw accelerometer, microphone and screen data and was run alongside KitKat, Lollipop, Marshmallow, Nougat, and Oreo
Android operating systems. The raw data from the app was encrypted, time-stamped, and uploaded to a secure online server. The processing
and analysis of the data was performed separately using computer-based Matlab software (R2018a; Mathworks, USA). “Others” include:
Samsung Galaxy Ace 4 SM-G357FZ, Samsung Galaxy Ace 2 GT-I8160, Samsung Galaxy S3 Mini GT-I8200N, LG Optimus 3G CX670, Samsung
Galaxy S III mini I8190, Samsung Galaxy J5 J500FN, Sony Xperia L C2105, Moto G LTE XT1039, Huawei Ascend G510, Samsung Galaxy S4 I9505.
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accuracies may simply reflect the prevalence of the out-
come of interest in the dataset. Data were therefore bal-
anced in a 1:1 ratio prior to the training of algorithms
for both CV schemes by randomly under-sampling the
majority class.
For 10-fold CV, to balance the dataset, an equal ran-
domly selected sample of recordings from participants
without the outcome of interest was merged with record-
ings with the outcome of interest, assuming independence
between recordings and ignoring within person correla-
tions. The recordings were randomized and partitioned
into 10 separate folds. In turn, each fold was set aside to
form the test set, on which the accuracy of the model,
trained using the remaining mutually exclusive 9 folds,
was tested. Ten repetitions of 10-fold CV, each with ran-
domly selected balanced recordings, were performed. Sim-
ilarly, datasets were randomly balanced by outcome for
LOSO CV, where only the single clinic recording per-
formed by participants at their clinic visit was analysed;
all home recordings were excluded. Home recordings
were excluded from LOSO CV in order to allow for a
direct comparison to be made with existing logistic
regression models (detailed below); a single set of clinical
data was matched to each smartphone recording
performed in clinic for LOSO CV, with the clinical data
also being fed into existing logistic regression models.5,9
LOSO CV involves each recording in turn forming the
test set, with the rest being used to train the model. Ten
repetitions of LOSO CV, each with randomly selected bal-
anced datasets, were performed.
Following both CV schemes (see Table S1 for descrip-
tion of modelling algorithm), the predicted probability of
each recording belonging to either group was compared
to the known future outcome. To summarize the accuracy
of predictions we calculated area under the curve (AUC)
values.
A level of redundancy is likely among the 998 smart-
phone features, with some being more important for the
prediction of certain outcomes than others. Feature rank-
ing was obtained using random forests (employing only
the training data that was balanced at each LOSO CV
iteration). The assigned predictor importance was aver-
aged across all trained models for a given outcome pre-
diction, to allow the ranking of features in order of
importance. We then trained models using the top 30
smartphone features.
In order to gauge the validity of our machine learning
approach and the strength of our smartphone features,
Table 1. Smartphone predictions: outcome definitions and exclusion criteria.
Future outcome in
18 months’ time Clinical tool Baseline exclusion Outcome definition
Falls Falls questionnaire Frequency
of self-reported falling
Exclusion of those already falling [at
least 1 fall in the preceding 6 months]
The onset of falls [at least one fall in the
6 months preceding their next 18-month visit]
Freezing Freezing of gait questionnaire18:
Question 3: “Do you feel that
your feet get glued to the
floor while walking, making
a turn or when trying to
initiate walking (freezing)?”
Exclusion of those already freezing [a
score ≥ 1 i.e. any answer other than
“Never”]
The onset of freezing [a score ≥ 1 in
18 months’ time]
Postural
instability
Hoehn and Yahr19 Exclusion of those with existing postural
instability [a stage ≥ 3]
The onset of postural instability [a stage
≥ 3 in 18 months’ time]
Cognitive
impairment
Montreal Cognitive
Assessment21
Exclusion of those with existing evidence
of cognitive impairment [a score < 26]
The onset of cognitive impairment
[A MoCA < 26 in 18 months’ time]†
Difficulty doing
hobbies
Movement Disorders Society-
Unified Parkinson’s Disease
Rating Scale part II22:
Question 2.8: “Over the past
week, have you usually had
trouble doing your hobbies or
other things that you like to do?”
Exclusion of those with existing moderate
to severe difficulty doing hobbies or
other activities of enjoyment [a
score ≥ 3]
The onset of major problems or an
inability to do hobbies or other
activities of enjoyment [a score ≥ 3
in 18 months’ time]
Need for help
at home
Social background questionnaire:
Self-reported need for help at home
Exclusion of those who are already
needing help at home
The onset of a need for help at home
Abbreviation: MoCA, Montreal Cognitive Assessment.
1A MoCA score < 26 has previously been found to be associated with a sensitivity of 86% and specificity of 72% in screening for individuals with defi-
cits on neuropsychological testing in at least two domains.33
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Figure 2. Flow charts demonstrating the time windows whose recordings were included in the analyses of the future onset of (A) falls, (B)
freezing, (C) postural instability, (D) cognitive impairment, (E) difficulty doing hobbies, and (F) need for help at home.
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we applied two existing logistic regression prediction
models to our clinical data and assessed the accuracy of
their predictions of (1) future freezing5 and (2) a com-
posite future adverse outcome of dementia, postural
instability, or death9 against those made using smart-
phone features, random forests and LOSO CV. Following
personal communication with an author of the paper,
direct MDS-UPDRS values for items 3.9, 3.13, 3.10, and
3.12 were substituted for UPDRS items 27-30 to form the
axial score. Future freezing and postural instability were
defined as before (Table 1). Dementia was defined
according to the presence of both objective cognitive
impairment (MoCA ≤ 20) as well as functional impair-
ment (Informant Questionnaire on Cognitive Decline in
the Elderly (IQCODE)>52).21,26
Results
A total of 1842 recordings performed by 237 participants
at 268 time windows were included in the analysis of one
or more outcomes (Fig. 2).
Clinical characteristics
Baseline clinical characteristics of participants at the time
of their smartphone recordings are presented in (Table 2).
Participants who developed falls, postural instability, and
cognitive impairment were significantly older than those
who did not. Participants who developed falls and freez-
ing had a longer disease duration from diagnosis and
higher motor examination scores on the MDS-UPDRS
part III. Those who developed postural instability and dif-
ficulty doing hobbies had lower MoCA scores and higher
MDS-UPDRS part III scores compared to those who did
not develop such future difficulty.
Model validation
It is likely that of the 998 smartphone derived features,
some may be collinear (redundant) and associated with
noise. Different sets of feature rankings were thus
obtained separately for each of the outcomes of interest.
Although multicollinearity can influence model inference,
it does not reduce the overall predictive accuracy of the
model. The results are displayed in (Fig. 3) and (Table 3).
Using all 998 features, AUC values of greater than 0.90
were achieved for all six outcomes. Using only the top 30
smartphone features, with the highest predictive power, a
reduction in the AUC values was seen though they
remain greater than 0.75 for both 10-fold CV and LOSO
CV. The effect of increment in feature number on predic-
tion accuracy (for 10-fold CV and LOSO CV) is demon-
strated in Figure S1.
Comparison with other models
Logistic regression models described by Ehgoetz et al. and
Velseboer et al. were applied to the clinical data from par-
ticipants who had contributed smartphone recordings and
the accuracy of their predictions assessed.5,9 As a com-
parator, smartphone recordings from the same partici-
pants were used to train machine learning algorithms
(random forests) which were validated using LOSO CV
(Table 4). For the prediction of future freezing, the LOSO
CV model using 30 smartphone features outperforms the
logistic regression model. Although to a lesser degree, the
same is true when using two smartphone features, equiva-
lent to the number of clinical variables in the logistic
regression model. Seven participants who contributed
smartphone recordings went on to develop dementia
(n = 2) and/or postural instability (n = 6) while at the
same time having the baseline clinical variables necessary
for the Velseboer et al. model. None of the participants
who contributed smartphone recordings had died by their
next clinic visit. For the prediction of the composite
adverse outcome of dementia, postural instability, or
death9 the AUC for the logistic regression model (0.81)
was slightly higher than that garnered through a machine
learning approach using the top 30 smartphone features
(0.76). When creating models, the lack of any formal CV
can result in over-fitting. Indeed, when a similar approach
is adopted to Ehgoetz et al., that is, when models are
trained and tested on the same data set, without any
splitting into independent train and test sets, inflated
AUC values of 1 for both the prediction of freezing and
the composite adverse outcome are obtained using a
machine learning approach.
Discussion
Prediction of disease progression and their milestones is a
challenge for clinicians and patients alike. We describe for
the first time the innovative use of a 7-min smartphone
test in isolation to predict future clinical and functional
change in early Parkinson’s. Using a simple smartphone
test, we can predict the onset of disease milestones
including falls, freezing, postural instability, and cognitive
impairment 18 months before occurrence with high levels
of accuracy. Predictions are made on an individual basis
using data from smartphone tests alone, without the need
for clinical examination scores or patient questionnaires.
A thorough evaluation of our machine learning approach
is performed using two CV schemes; (1) 10-fold CV and
(2) LOSO CV as well as (3) comparison with existing
logistic regression models. AUC values exceed 0.90 for
10-fold CV using all 998 smartphone features and 0.75
with a reduction to 30 features, using either CV scheme
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Figure 3. Receiver operating characteristic curves for classification by random forests in the prediction of the future onset of (A) falling, (B)
freezing, (C) postural instability, (D) cognitive impairment, (E) difficulty doing hobbies and (F) the need for help. The diagonal dotted line
corresponds to an AUC of 0.50 and indicates an uninformative model. The false positive rate (1-specificity) is shown on the x axis and the true
positive rate (sensitivity) is shown on the y axis.
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(see Table 1). Performance is comparable with/ signifi-
cantly better than that achieved with existing prediction
models which use combinations of different clinical ques-
tionnaires and assessments, requiring time and skill to
administer (see Table 2).5,9,19,27,28
These promising early results have the potential to pro-
vide people with Parkinson’s and those partnering in their
clinical care with greater information about their disease
course, identifying those at risk of developing a future
adverse outcome. In the age of limited clinical resources
and an aging population, it is conceivable that such risk
stratifying tools may assist in remote healthcare delivery,
allowing people with well controlled Parkinson’s to be
seen in person less frequently while those flagged as being
at risk of an adverse outcome could be offered closer clin-
ical surveillance. The cost effectiveness of such an
approach remains to be elucidated, but those at risk of
falls or postural instability could be referred for a falls
risk assessment to identify proactively falls risk factors
and modify these where appropriate.29 The earlier detec-
tion of those with freezing may also allow medication
adjustments to be made or cognitive training to be con-
sidered, with potential improvements in quality of
life.30,31
Limitations and strengths
In predicting future falls, freezing, difficulty doing hob-
bies, and the need for future help, we are limited by our
reliance on the accuracy of self-reported answers to sub-
jective questionnaires, with potential recall bias. In
recruiting participants diagnosed with Parkinson’s in life,
we are limited by the diagnostic accuracy of clinicians,
itself subject to significant variability, with pooled rates of
73.8% in non-experts rising to 83.9% in experts having
refined their diagnoses over time.32 In screening for cog-
nitive impairment, we chose a definition based on the
transition from a total MoCA score ≥ 26, to a MoCA
score < 26,21 in the absence of formal caregiver inter-
views. A MoCA score < 26 has previously been found to
be associated with a sensitivity of 86% and specificity of
72% in screening for individuals with deficits on neu-
ropsychological testing in at least two domains.33 Addi-
tionally, it allows classification of PD Mild Cognitive
Impairment according to MDS Task Force Level I crite-
ria,34 which, although subject to some temporal fluctua-
tion, has been shown to have prognostic value in
identifying patients at risk of developing future PD
dementia.35 Although the intention was to detect individ-
uals who may benefit from further cognitive evaluation,
neuropsychological assessments were not performed in
this study due to time constraints, but would be an
Table 3. Results of random forests analyses with 10-fold and leave
one subject out cross validation using all 998 and the top 30 smart-
phone features.
Prediction
AUC
10-fold CV
LOSO CV
998
features
Top 30
features
Top 30
features
Falls 0.94 0.88 0.79
Freezing 0.95 0.75 0.77
Postural Instability 0.90 0.91 0.79
Cognitive impairment 0.97 0.81 0.82
Difficulty doing hobbies 0.93 0.88 0.78
Need for help 0.99 0.85 0.83
Abbreviations: AUC, area under the curve, LOSO, leave one subject
out and CV, cross validation.
Table 4. Comparison with two existing logistic regression clinical prediction models for the prediction of future freezing and a composite adverse
outcome of cognitive impairment, postural instability, or death.
Prediction Method Input variables
AUC (95% confidence
intervals)1
Future freezing Logistic regression model as
described by Ehgoetz et al.5
Two clinical variables:Total FOG
score and HADS score
0.56 (0.44–0.67)
Random forests with LOSO CV Top 2 smartphone features 0.59 (0.55–0.64)
Random forests with LOSO CV Top 30 smartphone features 0.77 (0.73–0.80)
Composite adverse
outcome of dementia,
postural instability or death2
Logistic regression model as
described by Velseboer et al.9
three clinical variables:Animals
named, age and axial score
0.81 (0.40–0.96)
Random forests with LOSO CV Top 3 smartphone features 0.63 (0.52–0.71)
Random forests with LOSO CV Top 30 smartphone features 0.76 (0.68–0.84)
Abbreviations: AUC, area under the curve, FOG, Freezing of gait, HADS, Hospital anxiety and depression scale, LOSO CV, leave one subject out
cross validation.
1Confidence intervals for the logistic regression model are calculated across single predictions for each set of clinical data whereas confidence
intervals for LOSO CV are calculated using a bootstrapping approach; the two confidence intervals are therefore not directly comparable.
2No participants had died by the time of their next clinic visit.
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interesting avenue of future investigation, potentially
alongside the prospective evaluation of predictions in
independent cohorts.
Although the numbers we report are comparable with
similar studies seeking to predict future clinical outcomes,
our study includes relatively small numbers of partici-
pants who develop the outcomes of interest at their next
clinic visit.5,9 Although our results are encouraging, the
LOSO CV results in particular are likely to improve as we
continue to accrue data. The prediction accuracies
reported in this study were obtained using only a single
machine learning algorithm (random forests). As we
accrue more data, future studies could explore the efficacy
of using a range of different state-of-the-art classifiers that
may require larger training samples.
Comparing our smartphone approach with existing
clinical prediction models, it was necessary to make some
assumptions and extrapolations. The Velseboer et al.
model developed by the CARPA study and validated in
CamPaIGN was trained to predict a composite adverse
outcome of death, dementia and postural instability after
a 5-year period using baseline data.9 As participants in
the Discovery study do not perform Mini-Mental State
Examination (MMSE) assessments after their third visit,
we used a MoCA ≤ 20 with an IQCODE> 52 to define
dementia, as opposed to the original cut off of an
MMSE < 26. We excluded participants with a baseline
MoCA < 26 from analysis. As none of the participants
who performed smartphone assessments had died by their
next clinic visit, we are unable to assess the accuracy of
their model in predicting death. Given the adaptations
made it is encouraging that the AUC value associated
with the application of the logistic regression model to
our data as well as that achieved using trained machine
learning algorithms, are comparable with those published
by the authors of the original study.
In contrast, we were not able to achieve an AUC com-
parable to the values reported by Ehgoetz et al. when we
applied their logistic regression model to our clinical data.
Although the individuals who went on to develop freezing
at their follow up visit were of a similar number, age and
sex ratio, in the Ehgoetz et al. study they were on much
larger baseline levodopa equivalent doses and had signifi-
cantly higher levels of baseline anxiety than those who
did not develop freezing, whereas in our study such base-
line differences were not observed.
Our aim has been to use smartphone devices to mea-
sure symptom severity in a way that is potentially scalable
to large healthcare systems where resources are limited.
To that end, we elected to collect data in both clinical
and home environments without relying on cross-device
reproducibility, using a wide range of off-the-shelf con-
sumer grade smartphones (manufactured by major
international brands) that were equipped with a tri-axial
accelerometer (see Figure 1). Prioritising precision, the
vast majority of wearable device studies have recorded
data under highly controlled laboratory settings, using
exactly the same (often costly) hardware and software
across participants. This approach is likely to result in
higher quality data, as confounding effects due to varia-
tions in the in-built accelerometer are minimized. We
would therefore expect our use of different device settings
to be associated with slightly worse classification accura-
cies, than if the exact same smartphone model were used
across the cohort. However crucially, our study is scalable
as it does not depend on cross-device reproducibility,
leading to greater confidence in our interpretation of the
overall classification results.
To the best of our knowledge, this is the largest study of
its kind to use consumer-grade smartphones to capture
real-world data recordings from 237 people with Parkin-
son’s, studied longitudinally over 18 months. The Oxford
Discovery cohort comprises community-ascertained
patients and as such should more faithfully recapitulate dis-
ease evolution encountered in clinical practice. This study
demonstrates the tractability of simple smartphone record-
ings across large populations, to accurately predict future
clinically relevant outcomes. With time, our goal would be
to seek the registrations and approvals necessary to trans-
late our findings into routine clinical practice, with the ulti-
mate aim of improving the care of people with Parkinson’s.
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